Nature Communications (Feb 2021)
Mutant-selective degradation by BRAF-targeting PROTACs
Abstract
Hundreds of BRAF mutations have been identified in patients with cancer but currently approved drugs only target BRAF V600 mutants. Here, the authors develop a vemurafenib-based PROTAC that induces degradation of all classes of BRAF mutants without affecting wild-type RAF proteins.